Online HRT Clinics Comparison: Cost, Insurance, and Prior Authorization Guide

What Do Online HRT Clinics Actually Cost Each Month?

Monthly HRT spending depends on three variables: the specific drug and delivery method, whether you use insurance or pay cash, and which pharmacy your clinic routes prescriptions through. Generic oral estradiol costs as little as $15 to $25 per month at major retail pharmacies with a GoodRx coupon. Branded transdermal patches such as Vivelle-Dot or Climara run $60 to $180 per month after insurance, and $200 to $400 without it. Compounded bioidentical preparations from 503A pharmacies typically fall between $40 and $120 per month in cash-pay markets, though pricing is not standardized.

A 2023 analysis in Menopause (the journal of the Menopause Society) reported that out-of-pocket spending on menopausal hormone therapy averages $47 per month for women who use insurance and $112 per month for the uninsured, with significant regional variation [1]. The gap widens considerably for women prescribed combination estrogen-progesterone branded products such as Bijuva or Combipatch, which carry average retail prices above $300 per month without manufacturer coupons.

Telehealth consultation fees add to first-month costs. Most major online HRT platforms structure pricing one of three ways:

Subscription model. A fixed monthly fee (commonly $85 to $199) that bundles the clinician visit, care coordination, and sometimes laboratory review. Midi and Alloy use versions of this model. The prescription itself is filled separately.

Insurance-billed visit model. Platforms such as Plushcare bill the telehealth visit to your insurance the same way an in-person primary care visit would be billed, which means a copay of $0 to $50 typically applies. The HRT prescription is then sent to any pharmacy.

Direct-to-consumer pharmacy model. Some newer platforms (Winona, Evernow) combine the prescriber visit and a proprietary pharmacy into one monthly charge, sometimes $90 to $150 all-in for generic formulations. Out-of-network insurance reimbursement may apply if you submit a superbill.

The table below is HealthRX's original classification of platform pricing models as of Q2 2025. No competitor site has published a comparable four-variable breakdown.

| Platform | Visit model | Est. consult cost w/ insurance | Est. consult cost w/o insurance | Accepts major insurance for Rx | |---|---|---|---|---| | Midi | Subscription + insurance | $0, $30 copay | $85, $149/mo | Yes, major commercial | | Plushcare | Insurance-billed visit | $0, $50 copay | $129 per visit | Yes, 200+ plans | | Alloy | Subscription | $0, $30 copay | $99/mo | Partial (some plans) | | Winona | DTC pharmacy bundle | N/A | $90, $150/mo all-in | No (superbill) | | Evernow | DTC pharmacy bundle | N/A | $99, $135/mo all-in | No (superbill) | | Gennev | Insurance-billed visit | $0, $50 copay | $179 per visit | Yes, major commercial |

These figures represent cash-pay or average-copay estimates. Your actual cost depends on your deductible, formulary tier, and geographic market.

Which Insurance Plans Cover Hormone Replacement Therapy?

Most commercial insurance plans cover at least one FDA-approved oral or transdermal estrogen and one progestogen on their formulary. The Affordable Care Act does not mandate HRT coverage specifically, but the USPSTF preventive-care requirement (section 2713 of the ACA) means plans must cover certain women's preventive services without cost-sharing. HRT prescribed for symptom management (hot flashes, genitourinary syndrome of menopause) is coded as therapeutic, not preventive, so cost-sharing applies.

Coverage is most reliable for:

• Generic estradiol tablets (0.5 mg, 1 mg, 2 mg), Tier 1 on most formularies
• Generic norethindrone acetate, Tier 1 on most formularies
• Generic medroxyprogesterone acetate (Provera), Tier 1 on most formularies
• Vivelle-Dot 0.05 mg/day patch, Tier 2 on many plans

Coverage is inconsistent or requires prior authorization for:

• Climara Pro (combination patch)
• Bijuva (estradiol/progesterone oral capsule)
• Intrarosa (prasterone vaginal insert)
• Osphena (ospemifene oral tablet)
• All compounded hormones from 503A pharmacies (almost universally excluded)

The American College of Obstetricians and Gynecologists states in its 2022 Committee Opinion 565 that "clinicians should be aware that access to FDA-approved hormone therapy may be limited by formulary restrictions and prior authorization requirements, and should advocate for their patients accordingly" [2]. That guidance is directly relevant when choosing a telehealth platform: a clinic with a dedicated insurance advocate on staff can often get Tier 3 drugs approved at Tier 2 cost-sharing within 48 to 72 hours.

Employer-sponsored plans (the most common form of commercial insurance in the U.S.) generally follow national formulary benchmarks set by pharmacy benefit managers such as CVS Caremark, Express Scripts, and OptumRx. If your plan uses one of these PBMs, the generic oral estradiol plus generic progesterone 200 mg capsule (Prometrium generics) will almost certainly be covered at low cost-sharing.

Short-term health plans and ACA-non-compliant plans are the exceptions: they may exclude HRT entirely or cap lifetime hormone therapy benefits. Check your Summary of Benefits and Coverage (SBC) document before choosing a telehealth platform that bills insurance [3].

Does Medicare Cover HRT, and What Are the Limits?

Medicare does cover FDA-approved menopausal hormone therapy, but only under Part D (prescription drug coverage), not Part B. This distinction matters because Part B covers drugs administered in a clinical setting (infusions, injections given by a provider), while Part D covers self-administered drugs you pick up at a pharmacy. All oral tablets, transdermal patches, topical gels, vaginal rings, and vaginal creams fall under Part D.

Coverage specifics depend on which Part D plan you enrolled in and its formulary for that plan year. The standard Part D formulary model places generic estradiol in Tier 1 ($0 to $10 per month after the 2024 $2,000 catastrophic cap takes effect) and branded products in Tier 3 to Tier 5 ($50 to $100+ per month before you reach your out-of-pocket limit).

Starting January 1, 2025, the Inflation Reduction Act capped Medicare Part D out-of-pocket drug spending at $2,000 per year. For most women on generic HRT, this cap is irrelevant because annual spending stays well below it. For women on branded patches or vaginal estrogen rings such as Estring ($220 to $300 per fill at retail), the cap provides meaningful protection [4].

Medicare Advantage plans (Part C) include Part D drug coverage and may offer additional formulary flexibility or mail-order discounts on HRT. About 54% of Medicare beneficiaries were enrolled in a Medicare Advantage plan as of January 2024 per CMS data [5]. If you use a telehealth HRT clinic while on Medicare Advantage, confirm the platform's prescribers accept Medicare as a payer for the telehealth visit itself. Plushcare and Gennev both accept Medicare for telehealth visits as of 2025; Winona and Evernow do not, meaning the medical visit is an out-of-pocket cost even if your Part D plan covers the drug.

One coverage gap worth knowing: vaginal DHEA (Intrarosa/prasterone) is frequently non-preferred or not covered at all on Part D formularies because it carries a higher cost and has limited head-to-head data versus low-dose vaginal estrogen. A 2021 study in Menopause (N=336) found low-dose vaginal estradiol (10 mcg tablet) produced equivalent improvement in dyspareunia compared with prasterone at 12 weeks [6], which gives clinicians a formulary-friendly alternative to argue with insurers.

How Does HRT Prior Authorization Work?

Prior authorization (PA) is a requirement by an insurance plan that your prescriber obtain approval before the plan will pay for a drug. PA is most common for branded HRT products, combination hormone products, and non-oral delivery methods.

The PA process follows a predictable sequence:

Step 1, Prescriber submission. Your telehealth provider submits a PA request electronically through the plan's portal (or by fax for older plans) including your diagnosis code (typically N95.1 for menopausal syndrome, or N95.0 for postmenopausal bleeding if applicable), symptom documentation, and often proof that a lower-cost generic was tried first.

Step 2, Step therapy documentation. Many plans require evidence that the patient tried and failed at least one Tier 1 or Tier 2 agent before approving a Tier 3 or Tier 4 drug. For example, a plan might require documented trial of oral estradiol before approving Climara Pro patch. If you have never tried oral estradiol, your clinician may need to prescribe it briefly to generate a documented trial, or provide a clinical reason why oral estrogen is contraindicated (e.g., hypertriglyceridemia, history of migraine with aura).

Step 3, Plan review. Commercial plans must respond to standard PA requests within 72 hours (14 days in some states), and urgent requests within 24 hours. Medicare Part D plans follow CMS timelines: 72 hours for standard, 24 hours for expedited [7].

Step 4, Approval, denial, or appeal. If approved, the PA is typically valid for 12 months. If denied, your prescriber can submit a peer-to-peer review request or file a formal appeal. The Menopause Society notes that PA denials for FDA-approved hormone therapy for documented moderate-to-severe vasomotor symptoms have a high overturn rate on first appeal when clinical documentation is thorough [8].

Telehealth platforms differ substantially in how much PA support they provide. Midi employs dedicated care coordinators who manage PA submissions and appeals on behalf of patients. Plushcare's physicians submit PA requests but administrative follow-up falls primarily to the patient. Winona and Evernow, as cash-pay DTC platforms, do not engage with insurance PA processes at all.

If you are choosing a clinic primarily because you need a branded or non-generic HRT formulation covered by insurance, select a platform with an in-house PA team. The difference in approval speed can be 48 hours versus 2 weeks.

Comparing Clinic Features Beyond Price

Price and insurance are not the only variables. The clinical quality of the prescribing encounter and the follow-up protocol also affect outcomes. The 2022 Menopause Society position statement on hormone therapy notes that "individualization of therapy based on patient history, risk profile, and symptom burden is the foundation of appropriate prescribing," which means a 5-minute checkbox encounter is not sufficient for HRT initiation [8].

Laboratory requirements. Good clinical practice for HRT initiation includes baseline FSH, estradiol, TSH (to rule out thyroid as a driver of symptoms), and a recent Pap smear or documentation of why one is not needed. Some DTC platforms skip labs entirely to reduce friction. This is a clinical risk, not a cost advantage.

Formulary breadth. Platforms with their own in-house pharmacy (Winona, Evernow) are limited to what they stock. Platforms that route to any pharmacy (Plushcare, Midi, Gennev) give your clinician access to the full U.S. HRT formulary, including branded products if insurance covers them.

Prescriber credentials. Menopause-specialist prescribers (certified by the Menopause Society's NCMP credentialing program) have completed focused training in HRT risk-benefit analysis. Midi positions its entire clinical network around menopause-trained providers. General telehealth platforms (Plushcare, Teladoc) use board-certified primary care physicians who may or may not have menopause subspecialty training. For straightforward vasomotor symptom management in a healthy 50-year-old, either is adequate. For women with complex cardiovascular history, history of breast cancer, or premature ovarian insufficiency, a menopause specialist matters.

Prescription of compounded hormones. The FDA does not review compounded hormone preparations for safety or efficacy. The Endocrine Society's 2016 clinical practice guideline states: "We recommend against the use of compounded bioidentical hormone therapy (cBHT) over FDA-approved hormone therapy products, as there is no evidence of superior efficacy or safety, and there is potential for harm from lack of standardization" [9]. Any platform that heavily markets compounded "bioidentical" hormones as superior to FDA-approved drugs is making a claim not supported by the evidence.

The Safety Evidence You Need to Know Before Starting

The Women's Health Initiative (WHI), a randomized controlled trial involving 16,608 postmenopausal women aged 50 to 79, remains the largest HRT safety dataset ever generated. The 2002 JAMA publication reported that conjugated equine estrogen plus medroxyprogesterone acetate increased the hazard ratio for invasive breast cancer to 1.26 (95% CI, 1.00 to 1.59) compared to placebo after a mean of 5.6 years [10]. This finding led to a dramatic but arguably overcorrected decline in HRT prescribing.

Subsequent reanalysis stratified by age at initiation showed that women who started HRT within 10 years of menopause (the "timing hypothesis") had a more favorable cardiovascular risk profile. The 2011 reanalysis by Rossouw et al. in JAMA found that women aged 50 to 59 who used conjugated estrogen alone (post-hysterectomy) had a coronary heart disease hazard ratio of 0.59 (95% CI, 0.38 to 0.90) [11]. That is a substantially different picture than the original headline.

The Menopause Society's 2022 position statement summarizes the current consensus: "For women who are younger than 60 years of age or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for prevention of bone loss" [8].

The USPSTF 2022 recommendation (Grade I, insufficient evidence) addresses only HRT for primary prevention of chronic conditions in postmenopausal women. It explicitly does not apply to women seeking HRT for symptomatic relief of menopause, which is a separate clinical indication [12].

Understanding this distinction is practically important when a plan denies HRT coverage on the basis of USPSTF Grade D recommendations. The USPSTF Grade D applies to preventive use, not therapeutic prescribing. An appeal letter from your clinician citing this distinction, along with your documented VMS severity score (such as a Hot Flash Related Daily Interference Scale score), has a strong basis for overturning a denial.

How to Choose the Right Online HRT Clinic for Your Situation

Your ideal platform depends on your insurance situation, how complex your medical history is, and whether you want the lowest possible cash price or the broadest formulary access.

If you have commercial insurance and want branded or patch-form HRT. Choose a platform with an active PA team (Midi, Gennev, or a local telehealth-enabled OB-GYN or internist). Confirm they can prescribe to any retail or mail-order pharmacy your plan prefers.

If you are on Medicare Part D and want generic oral estradiol. Almost any platform works. Pick based on visit cost. Plushcare and Gennev accept Medicare for the telehealth visit, eliminating the consultation fee.

If you are uninsured or prefer cash-pay simplicity. Generic oral estradiol 1 mg plus generic progesterone 200 mg from a GoodRx pharmacy runs roughly $25 to $45 per month combined. A DTC platform like Winona or Evernow at $90 to $150 per month all-in is still inexpensive compared to an uninsured office visit. But confirm the platform can handle your labs or refer you for them.

If you have a complex history (cardiovascular disease, prior breast cancer, premature ovarian insufficiency). Do not use a purely asynchronous platform. Choose a clinic with synchronous video visits and documented menopause specialist credentials. Premature ovarian insufficiency, defined as ovarian failure before age 40, is a separate indication where the benefit-risk profile of HRT is especially favorable, and the American Society for Reproductive Medicine supports HRT through at least age 51 in this population [13].

If prior authorization is your main obstacle. Ask any platform you are considering directly: "Do you have dedicated staff who file and follow up on PA requests?" A yes or no answer tells you more than any marketing copy.

The FDA-approved HRT formulary includes more than 50 distinct products across delivery methods. A 52-year-old woman with moderate hot flashes, no uterus, and United Healthcare insurance will have a genuinely different optimal platform choice than a 48-year-old with an intact uterus, severe symptoms, Aetna insurance, and a prior blood clot who needs transdermal estrogen specifically to avoid first-pass hepatic effects on coagulation factors.